Revelation Biosciences IncNASDAQ REVB Stock Report

Revelation Biosciences, Inc. is a clinical-stage life sciences company, which focuses on the development of immunologic-based therapies for the prevention and treatment of disease. The company is headquartered in San Diego, California. The company went IPO on 2020-10-08. The firm is focused on the development and commercialization of immunologic therapeutics and diagnostics. Its therapeutic product candidates are based on its therapeutic platform and consist of REVTx-100, which is being developed for the prevention or treatment of infections, including those resulting from surgery, severe burns and antibiotic resistance; REVTx-200, which is being developed as intranasal therapy that focuses to be administered with a commercially available intramuscular (IM) vaccine; REVTx-300, which is being developed as a therapy for the treatment of chronic organ disease, including CKD and NASH; and REVTx-99b, which is being developed for the treatment of food allergies. The firm's diagnostic, REVDx-501 (REVIDTM Rapid Test Kit), is being developed as a rapid point of care or at home diagnostic product that can potentially be used to detect various respiratory viral infections.